touchONCOLOGY were joined by Dr Simon Crabb (Southampton University, UK) to discuss his presentation on the rucaparib arm of the ATLANTIS study, a randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma.
Questions
- Â What is the rationale for the use of PARP inhibitors in the treatment of metastatic urothelial cancer? 00:15-01:44
- What makes the ATLANTIS clinical trial design unique? 01:44-03:07
- What were the efficacy and safety findings of the ATLANTIS rucaparib arm? 03:07-04:25
- When will further results become available from the ATLANTIS clinical trial? 04:25-05:16
Speaker Disclosure: Simon Crabb discloses grant/research support from: Clovis Oncology, AstraZeneca and Roche, and is a member of the advisory board for: Bayer, Roche and AstraZeneca.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the Filmed in coverage of the ASCO Genitourinary Cancers Symposium 2022